All In Biotech

BLA 101995 · Smith and Nephew

Santyl

Collagenase · Topical

Novel

Last checked: Nov 20, 2026Latest source record: Jun 4, 1965 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1965

Jun 4, 1965

Approved uses

1

Original approval plus efficacy supplements

Registered trials

111

23 Phase 3, 4 recruiting

FAERS reports

1,690

1,022 serious, 486 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 17, 2019.

INDICATIONS AND USAGE Collagenase Santyl ◊ Ointment is indicated for debriding chronic dermal ulcers 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and severely burned areas. 3, 4, 5, 7, 16, 19, 20, 21

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 4, 1965 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • SANTYL · COLLAGENASE 250U/GRAM · OINTMENT, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Collagenase" as an intervention, any sponsor and status, largest first.

All 111 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death388
  • wound complication159
  • drug ineffective120
  • application site pain109
  • off label use68
  • pain64
  • impaired healing61
  • wound59
  • acute kidney injury52
  • chronic kidney disease52
  • nausea48
  • diarrhoea46

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20121
201321
201414
201550
2016115
2017136
2018171
2019163
202091
202177
2022147
2023112
2024139
2025227
2026225

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Santyl (Collagenase Clostridium Hist.)

2024 spending

$191M

Beneficiaries

139,140

260,947 claims

Per beneficiary

$1,374

$10.23 per unit

View as table
YearSpending
2020$161,167,361
2021$161,549,722
2022$169,161,129
2023$194,978,096
2024$191,148,727

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 305 on PubMed

Sponsor: Smith and Nephew

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.